Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obrixtamig plus carboplatin and etoposide versus standard platinum-etoposide for DLL3-positive advanced extrapulmonary neuroendocrine carcinoma
NL-OMON61124Phase 3Not yet recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of obrixtamig in extrapulmonary neuroendocrine carcinoma (EPNEC) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Overall survival. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
obrixtamig
03
Conditions
extrapulmonary neuroendocrine carcinoma (EPNEC)
Beyond the preview
Go deeper on NL-OMON61124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61124.